Navigation Links
GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients
Date:7/13/2009

ARLINGTON, Va., July 13 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on the Senate HELP Committee's vote on biogenerics legislation.

"While we are extremely disappointed that the Committee action could result in patients having little or no access to affordable biogenerics, we will continue to fight in the House to ensure that a true balance is achieved between innovation and competition. It is surprising that in the wake of the recent Federal Trade Commission report explicitly stating that 12 years of exclusivity would discourage innovation, the HELP Committee voted in favor of profits over patients. This unprecedented action strikes a huge blow to consumers at a time when many Americans are struggling to pay for the medicines they need.

"With generics saving the health care system $734 billion in the last decade, the House must now act to ensure that additional savings can be achieved by rejecting unnecessary and excessive years of market exclusivity for biopharmaceuticals. Over the last two years, we have dispelled the myths on the safety and efficacy of biogenerics that brand PhRMA and BIO tried to make to keep biogenerics from getting to consumers. It is now time to dispel the myth that double-digit years of exclusivity are needed to spark innovation. The White House already has the FDA working on creating a pathway and it has firmly stated that seven years of exclusivity is a good compromise. We must follow the course of the White House and Chairman Waxman and ensure that patients can truly access lifesaving biogeneric medicines in a timely manner.

"We hope that when the House Energy and Commerce Committee acts it follows the lead of its Chairman in approving a market exclusivity period that puts patients first. History has shown that a balance between innovation and competition can be achieved that benefits consumers and industry alike. Chairman Waxman knows this and we encourage him to continue to make patients the priority."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
3. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
4. International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
5. Kaiser Permanente CEO Calls for Connected Health Care
6. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
7. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
8. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
9. Bauer Calls Taxpayer-Funded Embryonic Stem Cell Research A Tragedy
10. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
11. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, ... Forecast to 2022", published by MarketsandMarkets, the global market is estimated to be ... Million by 2022, at a CAGR of 6.96% from 2016. ... ... Logo ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... society for optics and photonics , are commending the U.S. Congress and President ... signing Friday by the President of the American Innovation and Competitiveness Act (AICA). ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... cellular response analysis platform to measure the proteomic function of individual cells in ... Innovation Research (SBIR) grant from the National Institute on Aging of the National ...
(Date:1/11/2017)... England , PITTSBURGH and BENGALURU, ... -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE ... Food and Drug Administration (FDA) has accepted Mylan,s biologics ... for filing through the 351(k) pathway. This product is ... to treat certain HER2-positive breast cancers. The anticipated FDA ...
Breaking Biology Technology:
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):